Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a Healthcare company (Biotechnology) with a market capitalization of $8.1B. The Maz Rating grades it against the other companies in its sector.
Protagonist Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $124.83, Protagonist Therapeutics, Inc. trades at 24.4x trailing earnings, 14.9x sales and 7.7x book value, with an EV/EBITDA of 21.8. Over the last twelve months it generated about $548M of revenue and $334M of net income. It runs a gross margin of 99.7%, an operating margin of 58.6% and a net margin of 62.0%. It shows return on equity of 42.8%, return on invested capital of 28.9% and a free cash flow yield of 1.3%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 19.85. Over the past 52 weeks the share price ranged from $77.00 to $160.81, with a beta of 1.79.
Protagonist Therapeutics, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 26 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.